NCT02366819View on ClinicalTrials.gov

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

PHASE4RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 11, 2014

Primary Completion Date

June 8, 2026

Study Completion Date

June 8, 2026

Conditions
Esophageal AdenocarcinomaGastric AdenocarcinomaStage IIB Gastric CancerStage IIIA Esophageal AdenocarcinomaStage IIIA Gastric CancerStage IIIB Esophageal AdenocarcinomaStage IIIB Gastric CancerStage IIIC Esophageal AdenocarcinomaStage IIIC Gastric Cancer
Interventions
DRUG

Oxaliplatin

Given IV

DRUG

Leucovorin Calcium

Given IV

DRUG

Irinotecan Hydrochloride

Given IV

DRUG

Fluorouracil

Given IV

PROCEDURE

Conventional Surgery

Undergo surgery

Trial Locations (3)

60201

RECRUITING

Kellogg Cancer Center - Evanston Hospital, Evanston

RECRUITING

NorthShore University HealthSystem, Evanston

60637

RECRUITING

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER